Story
Braveheart Bio Raises $439.9 Million in Upsized Nasdaq IPO

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company, announced the closing of its upsized initial public offering, raising gross proceeds of $439.9 million. The successful debut provides the company with significant capital as it develops its lead drug candidate for a serious heart condition.
Offering Details
According to a company press release, Braveheart Bio sold a total of 24,437,500 shares of common stock at a price of $18.00 per share. The final share count was larger than initially planned due to the full exercise by underwriters of their option to purchase an additional 3,187,500 shares, a signal of strong investor demand.
The gross proceeds of $439.9 million are calculated before the deduction of underwriting discounts, commissions, and other offering-related expenses. All shares in the offering were sold by Braveheart Bio.
Market Debut and Pipeline
AdThe company's shares began trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol BRVE. The capital raised is expected to fund the development of its pipeline, led by its primary product candidate, BHB-1893.
BHB-1893 is an oral, small-molecule cardiac myosin inhibitor being developed to treat hypertrophic cardiomyopathy, a disease that causes the heart muscle to thicken. The drug is being studied for both obstructive and non-obstructive forms of the condition.
Underwriters and Regulatory Process
A consortium of investment banks managed the offering, with Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor serving as joint book-running managers. The registration statements for the offering were filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on August 5, 2026, clearing the final regulatory hurdle for the IPO.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.